RNA interference (RNAi) is the core discovery that forms the therapies Alnylam is developing. It is recognized as a major scientific breakthrough—but how does it work, exactly?
Learn about RNAi and our investigational therapiesRead More ›
Alnylam is focused on 4 Strategic Therapeutic Areas (STArs): genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases
Alnylam is dedicated to providing support for affected individuals, families, and caregivers
Interested in our clinical trials?